% | $
Quotes you view appear here for quick access.

BioLineRx, Ltd. Message Board

  • laujhawj laujhawj Mar 7, 2013 1:41 PM Flag

    IF ACAD's Pima Gets the Co's Market Cap to be ~$400M

    on just PDP alone, if BLRX's BL-1020 proves successful, for a much larger, much more complex Schizophrenia and 3-5 other RELATED diseases and symptoms, including Parkinson issues.... BLRX's market cap would LIKELY be between $300M-$600M.

    BLRX's bar, of course, is set much higher than either Pima or Risp (the latter being JJ's former blockbuster, still used as one of the kings in Schizophrenia, depression, Parkinson, Schizoaffective disorder, bi-polar, some autism, etc)... because BL-1020 aims to be a DUAL-ACTION molecule helping the immediate issues at-hand AS WELL AS improving memory/cognitive function...

    but from the SECOND ANALYSIS, released a few months ago, BL-1020 has a very good shot at being truly a "next generation" molecule... of these drugs that are dealing with these highly complex diseases and the symptoms --- physical and mental --- they produce.....

    the first, original analysis 2 plus years ago --- in comparison to both Placebo and RISP --- was "good;" but the SECOND ANALYSIS was so much more assuring.... as BL-1020 SEEMED to have show clear superiority to both Placebo and Risp, on both primary and secondary points... hopefully this interim analysis, mid March, uses the SAME EXACT patient examination and testing methods carried out by the independent anaylsis team noted as being the most optimal way to measure the safety and efficacy of BL-1020...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.958+0.097(+11.25%)Aug 24 4:00 PMEDT